John Pagel
Hematology & Oncology · Seattle, WANPI 1376633222
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $540,453 of the $724,565 with a category attached, or 74.6%. 17 manufacturers reported payments, led by AstraZeneca at 37.1% of the total. Among hematology & oncology clinicians in WA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 564 payments — averaging $1284.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$268K
- Gilead$131K
- Incyte Corporation$111K
- Epizyme, Inc.$41K
- Beigene USA, Inc.$41K
- Takeda Pharmaceuticals U.S.A., Inc.$34K
- plus $97K from 11 others
Across 355 payments — averaging $15,153 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$3.2M
- Gilead$830K
- Acerta Pharma LLC$780K
- Pharmacyclics LLC, An Abbvie Company$179K
- AbbVie$115K
- Seagen Inc.$75K
- plus $246K from 9 others
What the payments were for
- Consulting fees$121,24717%
- Speaking & faculty fees$540,45375%
- Travel & lodging$54,9688%
- Food & beverage$7,8971%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 188 | $268,484 |
| Gilead(2 entities) | 100 | $130,856 |
| Incyte Corporation | 95 | $111,360 |
| Epizyme, Inc. | 39 | $41,453 |
| Beigene USA, Inc. | 28 | $41,303 |
| Takeda Pharmaceuticals U.S.A., Inc. | 24 | $34,296 |
| Bristol Myers Squibb | 22 | $29,252 |
| Astrazeneca UK Limited | 6 | $25,003 |
| Verastem, Inc. | 18 | $13,357 |
| Adaptive Biotechnologies Corporation | 5 | $12,030 |
| Eli Lilly | 3 | $6,537 |
| Seagen Inc. | 3 | $6,110 |
| Morphosys, US Inc. | 1 | $3,075 |
| Johnson & Johnson | 29 | $843 |
| Pharmacyclics LLC, An Abbvie Company | 1 | $525 |
| Acerta Pharma LLC | 1 | $66 |
| Coherus Oncology, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$724,565 in reported general payments places this provider in the 95th percentile of 349 hematology & oncology providers in Washington.
Other hematology & oncology in Seattle
- John PesandoSeattle$15.7M
- Jill JohnsenSeattle$991K
- Fengting YanSeattle$841K
- Lawrence FongSeattle$546K
- Langdon MillerSeattle$457K
- Mazyar ShadmanSeattle$226K
- Catherine LeeSeattle$199K
- Celestia HiganoSeattle$164K
- Ryan CassadaySeattle$151K
- Rebecca Kruse-JarresSeattle$140K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.